Research and Development

Working with global partners’ state-of-the-art automated AI drug discovery platform and other emerging technologies, GT Apeiron aims at accelerating the development of novel drugs via new pathways to tackle high impact therapeutic targets and providing drug optimization, with an initial focus on oncology.

Apeiron is targeting the cancer cell cycle with a portfolio of next generation CDK inhibitors and harnessing synthetic lethal interactions in anti-cancer drug discovery.